Disease · MONDO_0005615

plasmacytoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. plasmacytoma. Diseases, record MONDO_0005615. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005615

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: plasmacytoma; Open Targets
Open Targets ID: MONDO_0005615; Open Targets
Disease Ontology: DOID:3721; Disease Ontology
MeSH: D010954; MeSH
NCI Thesaurus: C9349; NCI Thesaurus
Orphanet: ORPHA:86855; Orphanet
Highest stage of its drugs: Phase 2, for 6 of its 7 drugs, from ClinicalTrials.gov; Open Targets

Drugs7

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
LENALIDOMIDE	CHEMBL848	Small molecule	Phase 2	ClinicalTrials.gov	3	3	3	Drugs and targets
AVELUMAB	CHEMBL3833373	Antibody	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
AZACITIDINE	CHEMBL1489	Small molecule	Phase 2	ClinicalTrials.gov	1	1	0	Drugs and targets
BORTEZOMIB	CHEMBL325041	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
DARATUMUMAB	CHEMBL1743007	Antibody	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
DEXAMETHASONE	CHEMBL384467	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
DURVALUMAB	CHEMBL3301587	Antibody	Phase 1	ClinicalTrials.gov	1	1	1	Drugs and targets

Targets47

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
CD274	Programmed cell death 1 ligand 1	2	Programmed cell death 1 ligand 1 inhibitor; Programmed cell death 1 ligand 1 other	Phase 2	https://conductscience.org/library/genes/29126	Drugs and targets
ADRM1	26S proteasome	1	26S proteasome inhibitor	Phase 2	https://conductscience.org/library/genes/11047	Drugs and targets
CD38	ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1	1	Lymphocyte differentiation antigen CD38 inhibitor	Phase 2	https://conductscience.org/library/genes/952	Drugs and targets
CRBN	CRL4(CRBN) E3 ubiquitin ligase	1	CRL4(CRBN) E3 ubiquitin ligase inhibitor; CRL4(CRBN) E3 ubiquitin ligase modulator	Phase 2	https://conductscience.org/library/genes/51185	Drugs and targets
CUL4A	CRL4(CRBN) E3 ubiquitin ligase	1	CRL4(CRBN) E3 ubiquitin ligase inhibitor; CRL4(CRBN) E3 ubiquitin ligase modulator	Phase 2	https://conductscience.org/library/genes/8451	Drugs and targets
DDB1	CRL4(CRBN) E3 ubiquitin ligase	1	CRL4(CRBN) E3 ubiquitin ligase inhibitor; CRL4(CRBN) E3 ubiquitin ligase modulator	Phase 2	https://conductscience.org/library/genes/1642	Drugs and targets
DNMT1	DNA (cytosine-5)-methyltransferase 1	1	DNA (cytosine-5)-methyltransferase 1 inhibitor	Phase 2	https://conductscience.org/library/genes/1786	Drugs and targets
DNMT3A	DNA (cytosine-5)-methyltransferase 3A	1	DNA (cytosine-5)-methyltransferase 3A inhibitor	Phase 2	https://conductscience.org/library/genes/1788	Drugs and targets
NR3C1	Glucocorticoid receptor	1	Glucocorticoid receptor agonist	Phase 2	https://conductscience.org/library/genes/2908	Drugs and targets
PSMA1	26S proteasome	1	26S proteasome inhibitor	Phase 2	https://conductscience.org/library/genes/5682	Drugs and targets

1 to 10 of 47

See all 47 targets

Trials6

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT03910439	Avelumab in Combination With Hypofractionated Radiotherapy in Patients With Relapsed Refractory Multiple Myeloma	Phase 2	4	2021-04-20	Myeloma, Multiple, Myeloma-Multiple	AVELUMAB	Its record names the disease	ClinicalTrials.gov
NCT05248633	Chemotherapy Combined With Radiotherapy Versus Radiotherapy Alone for Solitary Plasmacytoma	Phase 2	220		Solitary Plasmacytoma	BORTEZOMIB, DEXAMETHASONE, LENALIDOMIDE	Open Targets' reading of its record	ClinicalTrials.gov
NCT06863584	SBRT Plus Lenalidomide for Solitary Plasmacytoma: Phase II Trial	Phase 2	41		Solitary Plasmacytoma	LENALIDOMIDE	Open Targets' reading of its record	ClinicalTrials.gov
NCT04065308	Daratumumab With DCEP for Multiple Myeloma With Plasmacytoma	Phase 2	33		Multiple Myeloma in Relapse, Plasmacytoma, Daratumumab	DARATUMUMAB	Its record names the disease	ClinicalTrials.gov
NCT04174196	A Study of Lenalidomide and CC-486 With Radiation Therapy in Patients With Plasmacytoma	Phase 2	21		Plasmacytoma, Plasmacytoma of Bone, Multiple Myeloma	LENALIDOMIDE	Its record names the disease	ClinicalTrials.gov
NCT03196401	A Study of Durvalumab (Anti-PDL1) Plus Radiation Therapy for the Treatment of Solitary Bone Plasmacytoma	Phase 1	0		Solitary Bone Plasmacytoma	DURVALUMAB	Open Targets' reading of its record	ClinicalTrials.gov

Comparisons in its trials0

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

None in this release.

Papers from its trials0

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

None in this release.

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005615

GET https://conductscience.org/api/diseases/v1/MONDO_0005615/targets?page=2

API reference For AI assistants